- Home
- ZTEK vs ASRT Comparison
ZTEK vs ASRT Comparison
Compare ZTEK & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZTEK | ASRT |
|---|---|---|
| Founded | 2008 | 1995 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 76.0M |
| IPO Year | 2022 | 2004 |
Fundamental Metrics
Financial Performance| Metric | ZTEK | ASRT |
|---|---|---|
| Price | $0.50 | $18.16 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 79.6K | ★ 279.8K |
| Earning Date | 02-18-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $118,713,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.61 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.46 | $0.57 |
| 52 Week High | $1.84 | $20.45 |
Technical Indicators
Market Signals| Indicator | ZTEK | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 36.74 | 64.47 |
| Support Level | N/A | $0.70 |
| Resistance Level | $0.57 | $20.45 |
| Average True Range (ATR) | 0.04 | 0.57 |
| MACD | -0.00 | -0.30 |
| Stochastic Oscillator | 34.32 | 6.33 |
Price Performance
Historical ComparisonAbout ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.